Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19290944 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | August 2025 | January 2026 | Allow | 5 | 0 | 1 | Yes | No |
| 19207781 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | May 2025 | September 2025 | Allow | 4 | 2 | 0 | No | No |
| 18946234 | FORMULATION PRODUCTION PROCESS | November 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18943165 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | August 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18943124 | NASAL COMPOSITIONS COMPRISING ALCAFTADINE | November 2024 | August 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18764277 | LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER | July 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18754044 | MULTIPLE MYELOMA TREATMENT | June 2024 | March 2026 | Allow | 21 | 2 | 0 | No | No |
| 18655511 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | May 2024 | August 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18650914 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | April 2024 | July 2025 | Allow | 15 | 3 | 1 | Yes | No |
| 18638097 | COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF | April 2024 | September 2025 | Allow | 17 | 3 | 1 | Yes | No |
| 18636653 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | April 2024 | November 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18611251 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | March 2024 | September 2025 | Allow | 18 | 2 | 0 | No | No |
| 18600852 | CDK Inhibitors And Their Use As Pharmaceuticals | March 2024 | November 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18595842 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18590002 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 | February 2024 | January 2026 | Allow | 23 | 1 | 0 | Yes | No |
| 18439926 | CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | February 2024 | October 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18430858 | PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS | February 2024 | July 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18426321 | PROTEOLYSIS-TARGETING CHIMERA MOLECULE AND PREPARATION METHOD AND USE THEREOF | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18424274 | TREATMENT OF CANCER WITH A RAF INHIBITOR | January 2024 | October 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18422922 | FORMULATION PRODUCTION PROCESS | January 2024 | August 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18420099 | Stable Pharmaceutical Compositions of Apixaban | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18416668 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER | January 2024 | June 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18412308 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | January 2024 | November 2024 | Allow | 10 | 0 | 1 | No | No |
| 18406455 | COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATION | January 2024 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18511018 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | November 2023 | June 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18388730 | 7-(4-((5-(BENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18506610 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | November 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18504388 | METHOD OF TREATING MAJOR DEPRESSIVE DISORDER | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18386565 | 3-(3-CHLOROPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18497515 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | October 2023 | November 2024 | Allow | 12 | 0 | 1 | No | No |
| 18495455 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | October 2023 | April 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18555659 | LAMOTRIGINE HYDRATE CRYSTAL FORM, PREPARATION METHOD THEREFOR, AND COMPOSITION CONTAINING SAME | October 2023 | December 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18282318 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | September 2023 | January 2026 | Allow | 28 | 0 | 0 | Yes | No |
| 18468453 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | September 2023 | November 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18461595 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | September 2023 | July 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18235026 | SEED GERMINATION ACTIVATOR FOR CONTROL OF BROOMRAPE | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18277653 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DENGUE FEVER | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18450256 | TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS | August 2023 | December 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18448124 | METHOD OF TREATING SCLC AND MANAGING NEUTROPENIA | August 2023 | April 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18448145 | METHOD OF TREATING SCLC AND MANAGING THROMBOCYTOPENIA | August 2023 | August 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18230039 | MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18357295 | Stable Pharmaceutical Compositions of Apixaban | July 2023 | September 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18350914 | MULTIPLE MYELOMA TREATMENT | July 2023 | September 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18213464 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | June 2023 | May 2025 | Allow | 23 | 2 | 1 | No | No |
| 18328109 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | June 2023 | September 2023 | Allow | 4 | 0 | 1 | No | No |
| 18325883 | LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER | May 2023 | April 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18313016 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | May 2023 | August 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18312162 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | May 2023 | August 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18301519 | PHARMACEUTICAL COMPOSITION AND METHODS OF USES | April 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18296726 | TREATMENT OF CANCER WITH A RAF INHIBITOR | April 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18295674 | KRAS Agonists, Pharmaceutical Compositions, and Uses in Managing Cancer | April 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18193122 | METHOD OF TREATING MAJOR DEPRESSIVE DISORDER | March 2023 | August 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18127211 | METHOD OF ADMINISTERING UPADACITINIB TO AVOID ADVERSE DRUG INTERACTIONS AND EFFECTS | March 2023 | December 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18189453 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | March 2023 | November 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18189613 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | March 2023 | December 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18187935 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | March 2023 | April 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18245794 | NEW COMPOUND | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18121238 | SEED GERMINATION ACTIVATOR FOR CONTROL OF BROOMRAPE | March 2023 | January 2024 | Allow | 10 | 2 | 1 | No | No |
| 18166150 | SHP2 Inhibitor Compositions and Methods for Treating Cancer | February 2023 | June 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18105372 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | February 2023 | October 2024 | Abandon | 21 | 2 | 0 | Yes | No |
| 18018997 | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Pharmaceutical Compositions, and Uses Thereof | January 2023 | March 2025 | Allow | 26 | 0 | 0 | No | No |
| 18102532 | METHODS OF TREATMENT OF TRIGEMINAL NEURALGIA | January 2023 | October 2025 | Abandon | 32 | 4 | 0 | No | No |
| 18102197 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | January 2023 | November 2025 | Abandon | 34 | 2 | 1 | No | No |
| 18006978 | CD151 INHIBITORS | January 2023 | August 2024 | Allow | 18 | 0 | 0 | Yes | No |
| 18101377 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | January 2023 | May 2024 | Allow | 16 | 1 | 0 | No | No |
| 18157510 | METHODS FOR ENHANCING VASCULAR DENSITY | January 2023 | February 2026 | Allow | 36 | 1 | 1 | Yes | No |
| 18157229 | CDK Inhibitors And Their Use As Pharmaceuticals | January 2023 | November 2023 | Allow | 10 | 0 | 1 | No | No |
| 18147070 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | December 2022 | November 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 18077929 | DOSING REGIMENS FOR USE IN TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH VENETOCLAX | December 2022 | February 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18061219 | PRMT5 INHIBITORS FOR OCULAR THERAPY | December 2022 | January 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18059024 | CANCER THERAPY BY DEGRADING DUAL MEK SIGNALING | November 2022 | July 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17993817 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS | November 2022 | March 2023 | Allow | 4 | 1 | 0 | No | No |
| 18057537 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | November 2022 | August 2024 | Allow | 21 | 2 | 1 | No | No |
| 17989382 | LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER | November 2022 | February 2024 | Abandon | 15 | 1 | 0 | No | No |
| 17998920 | TREATMENT FOR AMYLOIDOSIS | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17985015 | COMPOSITIONS AND METHODS OF TREATING CANCER | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17983762 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | November 2022 | December 2025 | Allow | 37 | 3 | 0 | No | No |
| 17981148 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL | November 2022 | July 2025 | Allow | 32 | 2 | 0 | No | No |
| 17921893 | METHODS OF TREATING CYTOKINE-RELATED ADVERSE EVENTS | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18048573 | REPLICATION STRESS PATHWAY AGENT COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2022 | February 2023 | Allow | 4 | 0 | 0 | No | No |
| 17995908 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | October 2022 | December 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17917995 | METHODS FOR TREATING CYTOKINE RELEASE SYNDROME | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17951326 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | September 2022 | August 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17934942 | Methods of Treating Eye Disorders | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17950642 | METHOD OF TREATING HYPERTENSION | September 2022 | December 2024 | Abandon | 27 | 2 | 1 | No | No |
| 17903208 | OMEGA-3 COMPOSITIONS | September 2022 | January 2026 | Allow | 40 | 5 | 0 | No | No |
| 17815958 | BENZOSELENOPHENE-BASED COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND ANTIBODY-DRUG CONJUGATE | July 2022 | December 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17876071 | CANNABIS COMPOSITION | July 2022 | July 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17814378 | SALTS, CRYSTAL FORMS, AND PRODUCTION METHODS THEREOF | July 2022 | January 2024 | Allow | 18 | 1 | 0 | No | No |
| 17868257 | COMPOSITIONS AND METHODS OF TREATING CARDIAC HYPERTROPHY AND HEART FAILURE | July 2022 | March 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17854027 | PHARMACEUTICAL COMPOSITIONS AND USES DIRECTED TO LYSOSOMAL STORAGE DISORDERS | June 2022 | January 2025 | Allow | 31 | 4 | 0 | Yes | No |
| 17790049 | TRIPTOLIDE ACRYLATE, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2022 | January 2023 | Allow | 7 | 0 | 0 | No | No |
| 17805331 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | June 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17825090 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | May 2022 | February 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17779048 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | May 2022 | July 2024 | Allow | 26 | 3 | 1 | Yes | No |
| 17750721 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | May 2022 | October 2023 | Allow | 17 | 1 | 0 | No | No |
| 17749376 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | May 2022 | July 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17742296 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER | May 2022 | October 2025 | Allow | 41 | 2 | 0 | No | No |
| 17772705 | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal | April 2022 | February 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17725081 | PARENTERAL DOSAGE FORM OF BETA 3 ADRENORECEPTOR AGONISTS | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSTURKO, GEORGE W.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOSTURKO, GEORGE W works in Art Unit 1621 and has examined 146 patent applications in our dataset. With an allowance rate of 73.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.
Examiner KOSTURKO, GEORGE W's allowance rate of 73.3% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KOSTURKO, GEORGE W receive 1.92 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KOSTURKO, GEORGE W is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.8% benefit to allowance rate for applications examined by KOSTURKO, GEORGE W. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 68% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 47.6% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 76.9% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.